Palbociclib: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1001138/Cv/1'> | ||
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6. <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]). <ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref> See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||